-
Expanding the Role of Neoadjuvant Chemoimmunotherapy in Borderline Resectable Stage III NSCLC
Dr. Biagio Ricciuti says the findings from a recently published study evaluating neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy suggest that chemoimmunotherapy can effectively downstage borderline resectable tumors and enable curative-intent surgery in patients who might otherwise be treated with definitive chemoradiotherapy alone.
More Recent News
-
Research Points to Translational Path Toward Precision Immunotherapies for EGFR-Mutant NSCLC
Dr. Yongfeng He said recent data show EGFR-L858R to be a shared, druggable neoantigen and provide a compelling rationale for the development of mutation-directed immunotherapies.
-
As Air Quality Protections Weaken, Advocates Call on Healthcare Community to Consider Implications for Public Health, Patient Care
Drs. Joan H. Schiller and Roselle de Guzman say championing public policies that prioritize clean air and incorporate environmental exposure histories into clinical care are the future of the field.